Analytical Data
-
基因名
EMCN
- Application
-
别名
EMCN；EMCN2；MUC14;Endomucin
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9ULC0
-
表达区间
1-261aa
-
氨基酸序列
MELLQVTILFLLPSICSSNSTGVLEAANNSLVVTTTKPSITTPNTESLQKNVVTPTTGTTPKGTITNELLKMSLMSTATFLTSKDEGLKATTTDVRKNDSIISNVTVTSVTLPNAVSTLQSSKPKTETQSSIKTTEIPGSVLQPDASPSKTGTLTSIPVTIPENTSQSQVIGTEGGKNASTSATSRSYSSIILPVVIALIVITLSVFVLVGLYRMCWKADPGTPENGNDQPQSDKESVKLLTVKTISHESGEHSAQGKTKN
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EMCN, or Endothelial Glycocalyx Layer Component, is a heparan sulfate proteoglycan predominantly expressed in endothelial cells, playing a crucial role in vascular biology and homeostasis. Research into EMCN has gained momentum due to its association with various physiological and pathological processes, including angiogenesis, inflammation, and tumor progression. The protein is instrumental in mediating cell adhesion, regulating vascular permeability, and influencing the interaction between endothelial cells and circulating immune cells. Dysregulation of EMCN expression or function has been implicated in several cardiovascular diseases, including atherosclerosis and hypertension, as well as in cancer metastasis. Consequently, EMCN is emerging as a potential biomarker for these conditions and a targeted therapeutic avenue. Understanding its structural properties and signaling pathways can provide insights into its functional roles, offering new possibilities for intervention strategies in diseases associated with endothelial dysfunction. Current research focuses on characterizing EMCN through recombinant protein technologies to explore its molecular mechanisms and potential applications in regenerative medicine and targeted therapies.
